General Information

(Note: IPOScoop has No Call on this small-cap unit offering. The listing here is a professional courtesy. This unit offering was upsized at pricing to 1,270,589 units, up from 1,058,824 units in the prospectus, and priced at $17 – the midpoint of its $16-to-$18 range. Each unit consists of common stock, Series A warrants and Series B warrants.)

GBS is developing and commercializing a range of Biosensor-based Point of Care (“POCT”) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Given the COVID-19 pandemic, the superior analytical characteristics of the biosensor technology and the advanced development stage, the company decided to expedite a collaboration with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss) to develop a more accurate and real-time SARS-CoV-2 test for diagnostic, point-of-care screening and pre-vaccination screening.

GBS is the global licensee and intends to introduce and launch COV2 diagnostic tests across the U.S., Europe, APAC (the Asia Pacific Region) and the rest of the world through appropriately qualified sublicensees and distributors.

Our flagship product candidate is the Saliva Glucose Biosensor, a POCT expected to substitute the finger-pricking invasive blood glucose monitoring for diabetic patients. On May 1, 2020, our parent company, Life Science Biosensor Diagnostics Pty Ltd (“LSBD”), filed a submission with the FDA for the Saliva Glucose Biosensor Diagnostic Test, currently in development as a point-of-care test intended to replace blood glucose testing for diabetes management.




Employees: 9
Founded: 2016
Contact Information
Address 708 Third Avenue, 6th Floor, New York, NY 10017, US
Phone Number (646) 828-8258
Web Address
View Prospectus: GBS
Financial Information
Market Cap $177.14mil
Revenues $0 mil (last 12 months)
Net Income $-7.3 mil (last 12 months)
IPO Profile
Symbol GBS
Exchange NASDAQ
Shares (millions): 1.3
Price range $17.00 - $17.00
Est. $ Volume $21.6 mil
Manager / Joint Managers Dawson James Securities
CO-Managers -
Expected To Trade: 12/23/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change